Literature DB >> 8045940

Identification of a DNA sequence involved in osteoblast-specific gene expression via interaction with helix-loop-helix (HLH)-type transcription factors.

M Tamura1, M Noda.   

Abstract

To elucidate regulatory mechanism(s) underlying differentiation of osteoblasts, we examined involvement of helix-loop-helix (HLH)-type transcription factors in osteoblast-specific expression of a phenotypic marker gene which encodes osteocalcin, a major noncollagenous bone matrix protein, exclusively expressed in osteoblasts. Overexpression of a dominant negative HLH protein, Id-1, decreased the activity of the 1.1-kb osteocalcin gene promoter cotransfected into rat osteoblastic osteosarcoma ROS17/2.8 cells. Analysis of deletion mutants revealed that a 264-bp fragment of osteocalcin promoter (-198 to +66) was sufficient for the Id-1-dependent suppression. Furthermore, the activity of the same promoter fragment (-198 to +66) was enhanced when antisense Id-1 expression vector was cotransfected. This osteocalcin gene promoter region contains two sites of an E-box motif, a consensus binding site for HLH proteins, which we refer to as OCE1 (CACATG, at -102) and OCE2 (CAGCTG, at -149), respectively. Mutagenesis in OCE1 but not OCE2 led to greater than 50% reduction in transcriptional activity of the osteocalcin gene promoter. Electrophoresis mobility shift assay indicated that factors in nuclear extracts prepared from ROS17/2.8 cells bound to the 30-bp oligonucleotide probe containing the E-box motif of OCE1. This binding was competed out by OCE1 oligonucleotide but neither by OCmE1 oligonucleotide in which E-box motif was mutated nor by OCE2. The OCE1-binding activity in the nuclear extracts of ROS17/2.8 cells was reduced by 70% when bacterially expressed Id-1 protein was added to the reaction mixture, suggesting the involvement of HLH proteins in the DNA/protein complex formation. In contrast to the osteoblast-like cells, OCE1-binding activity in the nuclear extracts of C3H10T1/2 fibroblasts was very low. However, when these fibroblasts were treated with recombinant human bone morphogenetic protein-2 which induced expression of osteocalcin as well as other phenotypic markers of osteoblasts, OCE1-binding activity was increased approximately 40-fold, indicating that OCE1 would be involved in the tissue-specific expression of the osteocalcin gene. These findings indicated for the first time that osteoblast-specific gene transcription is regulated via the interaction between certain E-box binding transcription factor(s) in osteoblasts and the OCE1 sequence in the promoter region of the osteocalcin gene.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8045940      PMCID: PMC2120135          DOI: 10.1083/jcb.126.3.773

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  51 in total

1.  Two distinct transcription factors that bind the immunoglobulin enhancer microE5/kappa 2 motif.

Authors:  P Henthorn; M Kiledjian; T Kadesch
Journal:  Science       Date:  1990-01-26       Impact factor: 47.728

2.  MyoD is a sequence-specific DNA binding protein requiring a region of myc homology to bind to the muscle creatine kinase enhancer.

Authors:  A B Lassar; J N Buskin; D Lockshon; R L Davis; S Apone; S D Hauschka; H Weintraub
Journal:  Cell       Date:  1989-09-08       Impact factor: 41.582

3.  1,25-dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene.

Authors:  N A Morrison; J Shine; J C Fragonas; V Verkest; M L McMenemy; J A Eisman
Journal:  Science       Date:  1989-12-01       Impact factor: 47.728

4.  Identification of MRF4: a new member of the muscle regulatory factor gene family.

Authors:  S J Rhodes; S F Konieczny
Journal:  Genes Dev       Date:  1989-12       Impact factor: 11.361

5.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction.

Authors:  S N Ho; H D Hunt; R M Horton; J K Pullen; L R Pease
Journal:  Gene       Date:  1989-04-15       Impact factor: 3.688

6.  Activation of muscle-specific genes in pigment, nerve, fat, liver, and fibroblast cell lines by forced expression of MyoD.

Authors:  H Weintraub; S J Tapscott; R L Davis; M J Thayer; M A Adam; A B Lassar; A D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

7.  DNA sequences in the rat osteocalcin gene that bind the 1,25-dihydroxyvitamin D3 receptor and confer responsiveness to 1,25-dihydroxyvitamin D3.

Authors:  M B Demay; J M Gerardi; H F DeLuca; H M Kronenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

8.  Identification of multiple glucocorticoid receptor binding sites in the rat osteocalcin gene promoter.

Authors:  A A Heinrichs; R Bortell; S Rahman; J L Stein; E S Alnemri; G Litwack; J B Lian; G S Stein
Journal:  Biochemistry       Date:  1993-10-26       Impact factor: 3.162

9.  Identification of a myocyte nuclear factor that binds to the muscle-specific enhancer of the mouse muscle creatine kinase gene.

Authors:  J N Buskin; S D Hauschka
Journal:  Mol Cell Biol       Date:  1989-06       Impact factor: 4.272

10.  Vitamin D-mediated modifications in protein-DNA interactions at two promoter elements of the osteocalcin gene.

Authors:  E R Markose; J L Stein; G S Stein; J B Lian
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

View more
  16 in total

1.  A TWIST in the fate of human osteoblasts identifies signaling molecules involved in skull development.

Authors:  E W Jabs
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

2.  p53 and MDM2 are involved in the regulation of osteocalcin gene expression.

Authors:  Hankui Chen; Kevin Kolman; Natalie Lanciloti; Michael Nerney; Emily Hays; Chet Robson; Nalini Chandar
Journal:  Exp Cell Res       Date:  2012-03-03       Impact factor: 3.905

3.  Intracellular mRNA cleavage by 3' tRNase under the direction of 2'-O-methyl RNA heptamers.

Authors:  Masato Tamura; Chikako Nashimoto; Noriko Miyake; Yasushi Daikuhara; Kozo Ochi; Masayuki Nashimoto
Journal:  Nucleic Acids Res       Date:  2003-08-01       Impact factor: 16.971

Review 4.  Nuclear microenvironments support physiological control of gene expression.

Authors:  Gary S Stein; Jane B Lian; Martin Montecino; Janet L Stein; André J van Wijnen; Amjad Javed; Jitesh Pratap; Je Choi; S Kaleem Zaidi; Soraya Gutierrez; Kimberly Harrington; Jiali Shen; Daniel Young; Shirwin Pockwinse
Journal:  Chromosome Res       Date:  2003       Impact factor: 5.239

Review 5.  Tissue specific and vitamin D responsive gene expression in bone.

Authors:  C White; E Gardiner; J Eisman
Journal:  Mol Biol Rep       Date:  1998-01       Impact factor: 2.316

6.  E proteins regulate osteoclast maturation and survival.

Authors:  Courtney L Long; William L Berry; Ying Zhao; Xiao-Hong Sun; Mary Beth Humphrey
Journal:  J Bone Miner Res       Date:  2012-12       Impact factor: 6.741

Review 7.  The osteocalcin gene: a model for multiple parameters of skeletal-specific transcriptional control.

Authors:  G S Stein; J B Lian; A J van Wijnen; J L Stein
Journal:  Mol Biol Rep       Date:  1997-08       Impact factor: 2.316

8.  NeuroD2 and neuroD3: distinct expression patterns and transcriptional activation potentials within the neuroD gene family.

Authors:  M B McCormick; R M Tamimi; L Snider; A Asakura; D Bergstrom; S J Tapscott
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

9.  Regulation of mRNA expression of matrix extracellular phosphoglycoprotein (MEPE)/ osteoblast/osteocyte factor 45 (OF45) by fibroblast growth factor 2 in cultures of rat bone marrow-derived osteoblastic cells.

Authors:  Gui Xia Zhang; Morimichi Mizuno; Kiyomi Tsuji; Masato Tamura
Journal:  Endocrine       Date:  2004-06       Impact factor: 3.633

10.  Prostate cancer cells modulate osteoblast mineralisation and osteoclast differentiation through Id-1.

Authors:  H-F Yuen; Y-T Chiu; K-K Chan; Y-P Chan; C-W Chua; C M McCrudden; K-H Tang; M El-Tanani; Y-C Wong; X Wang; K-W Chan
Journal:  Br J Cancer       Date:  2009-12-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.